Preclinical Cell Study Suggests Choline-Enriched Folate Form May Boost Methylation Activity

Balchem Corporation has published results from an in vitro study evaluating how its folate ingredient, Optifolin+, a choline-enriched form of (6S)-5-methyltetrahydrofolate, behaves inside human liver cells, reporting increases in a key methyl-donor metabolite and in DNA methylation activity.¹

The study, conducted with researchers at the University of Arkansas for Medical Sciences and published in the Journal of Dietary Supplements, used HepaRG cells, a human hepatocyte cell line commonly used to model liver metabolism, rather than human participants.²

For manufacturers formulating folate ingredients into healthy aging or epigenetic-support products, the findings offer additional mechanistic data, though notably from a cell model rather than a clinical trial.

Balchem has positioned the research as evidence that the ingredient's choline-enriched structure translates into measurable cellular activity, framing the results as a scientific basis for further development of folate products aimed at healthy aging and epigenetic support rather than as a finished clinical claim.¹

What Did the Cell Study on Optifolin+ Actually Measure?

The study exposed HepaRG cells to the ingredient over a 96-hour period and measured changes in methyl-donor metabolites and DNA methylation patterns, including repetitive-element methylation, a marker researchers use to assess genomic stability.²

According to the company's summary of the findings, exposure to Optifolin+ increased cellular S-adenosylmethionine, the primary methyl donor used in DNA methylation reactions, by 71%, and enhanced DNA methylation activity by as much as 14-fold compared to controls.

Balchem also cited internally calculated figures describing a 98% methyl capacity and what it termed a sevenfold methyl agent advantage relative to other folate forms, though the underlying calculations for those 2 figures were not detailed in the public announcement.

Why Does Methylation Capacity Matter to Formulators Working in Healthy Aging?

Methylation, the transfer of methyl groups onto DNA and other molecules, is a well-established biological process tied to gene expression regulation and is frequently discussed in aging and epigenetics research. Adequate folate status is necessary for normal methylation metabolism, and genetic variation in folate-metabolizing enzymes, most notably the MTHFR gene, is documented to affect how efficiently some individuals convert folic acid into its active form.³

That variability has driven interest among ingredient suppliers in offering already-active folate forms, such as 5-methyltetrahydrofolate, as an alternative to synthetic folic acid, positioning products like Optifolin+ within a broader shift already underway in the folate ingredient category rather than as an isolated innovation.

How Does This Cell Data Relate to Earlier Human Research on the Ingredient?

Optifolin+ has separately been evaluated in a randomized, double-blind, crossover pharmacokinetic study in 24 healthy adults, which found the ingredient reached peak blood concentrations faster and produced higher folate status markers than an equivalent dose of folic acid, without the buildup of unmetabolized folic acid sometimes associated with synthetic supplementation.⁴

That earlier trial addressed absorption and blood folate levels in humans; it did not measure downstream methylation activity, which is the gap the newer HepaRG cell study was designed to explore at the cellular level.

What Are the Limitations of This Cell-Based Research?

Because the newly published research was conducted entirely in a hepatocyte cell model rather than in human subjects, its findings describe biological plausibility rather than confirmed physiological outcomes in people consuming the ingredient.

Cell culture systems can respond to compound exposure differently than intact human metabolism, and the study did not report on dosing translation, safety endpoints, or methylation outcomes in living subjects. Balchem's own framing describes the results as a scientific foundation for further development rather than as evidence of a specific health outcome, and no human methylation trial for Optifolin+ has yet been published alongside this cell-based data.

References

1. New study shows Optifolin+® demonstrates superior methylation capacity. Balchem Corporation. September 10, 2026. Accessed September 14, 2026. https://balchem.com/news/hnh-study-superior-methylation-capacity/

2. Clement K, McGill MR, Bimali M, Koturbash I. (6S)-5-Methyltetrahydrofolate dicholine salt modulates methyl-donor metabolites and repetitive-element DNA methylation in HepaRG cells. J Diet Suppl. Published online 2026. doi:10.1080/19390211.2026.2680313

3. MTHFR gene variant and folic acid facts. . Centers for Disease Control and Prevention. July 16, 2026. Accessed September 14, 2026. https://www.cdc.gov/folic-acid/data-research/mthfr/index.html

4. Schön C, Micka A, Menzel D, Wilhelm M, Obeid R. Pharmacokinetics of (6S)-5-methyltetrahydrofolate dicholine salt compared to folic acid: a randomized double-blind single dose cross-over study. Food Nutr Res. 2025;69. doi:10.29219/fnr.v69.12633